Jim Cramer is ready for another chaotic week of earnings and recommended investors do their full homework before buying. » Read More
The Brexit bounce back that lifted stocks in July is unlikely to carry into August, and markets will be put to the test early on.
Wall Street — and the stock market — may now be comfortable with the idea of a Hillary Clinton victory, but her policies could be negative for many companies.
WASHINGTON— Institute for Supply Management releases its manufacturing index for July, 10 a.m.; Commerce Department releases construction spending for June, 10 a.m.. WASHINGTON— Commerce Department releases personal income and spending for June, 8:30 a.m.. TOKYO— Honda reports fiscal first quarter results.
Bayer surpassed second-quarter earnings expectations and raised its guidance for the year on strong gains in stroke prevention pill Xarelto.
The Associated Press reported Monday that it appears Arkansas had obtained a paralytic drug made by a subsidiary of Pfizer for use in executions. Pfizer has said it doesn't want its drugs used that way and that it has safeguards in place to prevent it from happening. Doug House, a Republican from North Little Rock, said Tuesday that while Pfizer may complain about...
LITTLE ROCK, Ark.— An execution drug obtained by the Arkansas prison system earlier this month appears to have been made by a subsidiary of Pfizer, even though the pharmaceutical giant has said it doesn't want its drugs to be used in executions. It matches labels submitted to the National Institutes of Health by Hospira, Inc., which Pfizer bought last year.
Mark Schoenebaum, Evercore ISI analyst, discusses his thoughts on the biotech rally.
Washington regulators are scuttling deals like it’s nobody’s business. Perhaps, it isn’t.
Jim Lebenthal discusses three names that he believes provides safety.
Donald Trump signaled that big banks could be a short bet if he wins office, but his presidency could help plenty of other companies.
"FMHR" resident value investor Jim Lebenthal has his eyes on three value stocks he says are breaking out this year. The "FMHR" traders and Stephanie Link, TIAA Global Asset Management, weigh in.
Investors should skip buying Merck shares because of valuation and political risk, BMO Capital said.
Jim Cramer broke down why bonds with negative yields are disastrous for investors.
Jim Cramer warned of lunatics pushing these investments to investors that are the absolute worst thing money can buy.
Jim Cramer highlights one group that was a clear winner of the first half of 2016.
Some of the names on the move ahead of the open.
Jim Cramer opened up the lesson book and shared his top blunders made on Wall Street.
Jim Cramer opens up the lesson book and shares his top blunders made on Wall Street.
Pfizer will disclose that painkillers can carry serious risk of addiction and promised not to promote opiates for unapproved uses.
U.S. cancer drug company Medivation is discussing opening its books to Sanofi, people familiar with the matter said on Tuesday.